Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Larry Maxwell

Showing results (131-140 of 158) with videos related to

Pageof 16
Sort By:
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Scientific Reports|May 1, 2021
Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patientsNicholas W Bateman, Christopher M Tarney, Tamara Abulez, et al.
Gynecologic Oncology|August 28, 2023
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatmentWei Ao, Hong Im Kim, Domenic Tommarello, et al.
Gynecologic Oncology|April 5, 2011
Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammationG Larry Maxwell, Brian L Hood, Roger Day, et al.
JAMA Network Open|May 15, 2025
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical HysterectomyChristopher M Tarney, Chunqiao Tian, Leslie M Randall, et al.
Cancer|June 28, 2017
Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patientsNicholas W Bateman, Elizabeth A Dubil, Guisong Wang, et al.
Clinical Proteomics|October 6, 2025
Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancersChristopher M Tarney, Paulette Mhawech-Fauceglia, Jonathan D Ogata, et al.
Scientific Reports|August 3, 2019
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian CancerStephen Shuford, Christine Wilhelm, Melissa Rayner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 3, 2026
Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium studyAngela Nolin, Morgan D Brown, Samantha M Thomas, et al.
JAMA Network Open|April 17, 2023
Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine CancerCalen W Kucera, Chunqiao Tian, Christopher M Tarney, et al.
Pageof 16

Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Scientific Reports|May 1, 2021
Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patientsNicholas W Bateman, Christopher M Tarney, Tamara Abulez, et al.
Gynecologic Oncology|August 28, 2023
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatmentWei Ao, Hong Im Kim, Domenic Tommarello, et al.
Gynecologic Oncology|April 5, 2011
Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammationG Larry Maxwell, Brian L Hood, Roger Day, et al.
JAMA Network Open|May 15, 2025
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical HysterectomyChristopher M Tarney, Chunqiao Tian, Leslie M Randall, et al.
Cancer|June 28, 2017
Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patientsNicholas W Bateman, Elizabeth A Dubil, Guisong Wang, et al.
Clinical Proteomics|October 6, 2025
Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancersChristopher M Tarney, Paulette Mhawech-Fauceglia, Jonathan D Ogata, et al.
Scientific Reports|August 3, 2019
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian CancerStephen Shuford, Christine Wilhelm, Melissa Rayner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 3, 2026
Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium studyAngela Nolin, Morgan D Brown, Samantha M Thomas, et al.
JAMA Network Open|April 17, 2023
Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine CancerCalen W Kucera, Chunqiao Tian, Christopher M Tarney, et al.
Pageof 16